Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Key facts

Sponsor

Dennis M. McNamara, MD, MS

Principal Investigator

Dennis McNamara, md

University of Pittsburgh

Intervention

Bromocriptine(drug)

Enrollment

250 target

Eligibility

18 years · FEMALE

Timeline

2022 – 2028

Study locations (30)

• University of Alabama Birmingham, Birmingham, Alabama, United States
• University of Arizona Sarver Heart Center, Tucson, Arizona, United States
• University of California San Diego, La Jolla, California, United States
• Keck School of Medicine of USC, Los Angeles, California, United States
• Cedars-Sinai Medical Center, Los Angeles, California, United States
• University of California Irvine Health, Orange, California, United States
• Stanford University, Stanford, California, United States
• University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
• Hartford Hospital, Hartford, Connecticut, United States
• Yale University, New Haven, Connecticut, United States
• University of Florida, Gainesville, Florida, United States
• Mayo Clinic, Florida, Jacksonville, Florida, United States
• University of South Florida, Tampa, Florida, United States
• Emory University, Atlanta, Georgia, United States
• Northwestern University, Chicago, Illinois, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Peripartum cardiomyopathy

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT05878041
  Creation of a Multicenter National Registry for Peripartum Cardiomyopathy.
  Federico II University

See all trials for Peripartum cardiomyopathy →